Favorable outcome associated with an IGF-1 ligand signature in breast cancer

Breast Cancer Research and Treatment

Volumn 133, Issue 1, 2012, Pages 321-331

  Mu, Lina ^a,e   Tuck, David ^a   Katsaros, Dionyssios ^b,c   Lu, Lingeng ^a   Schulz, Vincent ^a   Perincheri, Sudhir ^a   Menato, Guido ^b,c   Scarampi, Luca ^b,c   Harris, Lyndsay ^d,f   Yu, Herbert ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c S ANNA HOSPITAL   (Italy)

^d YALE CANCER CENTER   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Gene expression profiling; IGF 1 ligand; IGF I axis; IGF1 receptor

Indexed keywords

ADIPOCYTE GROWTH FACTOR; ANTINEOPLASTIC AGENT; GROWTH FACTOR; HORMONE; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN BINDING PROTEIN 7; SOMATOMEDIN BINDING PROTEIN LIGAND 1; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FOLLOW UP; GENE EXPRESSION PROFILING; GENOMICS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; KAPLAN-MEIER ESTIMATE; LIGANDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, IGF TYPE 1; YOUNG ADULT;

EID: 84860350494     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-1952-5     Document Type: Article

References (47)

1. J Bonneterre JP Peyrat R Beuscart A Demaille 1990 Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer Cancer Res 50 21 6931 6935 2170011 1:STN:280:DyaK3M%2FgsVSltg%3D%3D (Pubitemid 20361093)
2. G Blum A Gazit A Levitzki 2003 Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics J Biol Chem 278 42 40442 40454 12869569 10.1074/jbc.M305490200 1:CAS:528:DC%2BD3sXotFWhurs%3D (Pubitemid 37280854)
3. D Burtrum Z Zhu D Lu DM Anderson M Prewett DS Pereira, et al. 2003 A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo Cancer Res 63 24 8912 8921 14695208 1:CAS:528:DC%2BD3sXhtVSqtbvL (Pubitemid 38064071)
4. MN Pollak ES Schernhammer SE Hankinson 2004 Insulin-like growth factors and neoplasia Nat Rev Cancer 4 7 505 518 15229476 10.1038/nrc1387 1:CAS:528:DC%2BD2cXlt1Oktro%3D (Pubitemid 38868620)
5. E Surmacz 2003 Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor Oncogene. 22 42 6589 6597 14528284 10.1038/sj.onc.1206772 1:CAS:528:DC%2BD3sXnsl2rsrg%3D (Pubitemid 37372339)
6. R Baserga PM Glazer BC Turner BG Haffty L Narayanan J Yuan, et al. 1997 Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation Cancer Res 57 15 3079 3083 9242428 (Pubitemid 27351714)
7. D Sachdev JS Hartell AV Lee X Zhang D Yee 2004 A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells J Biol Chem 279 6 5017 5024 14615489 10.1074/jbc.M305403200 1:CAS:528: DC%2BD2cXpslSitw%3D%3D (Pubitemid 38199098)
8. CJ Creighton A Casa Z Lazard S Huang A Tsimelzon SG Hilsenbeck, et al. 2008 Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis J Clin Oncol 26 25 4078 4085 18757322 10.1200/JCO.2007.13.4429 1:CAS:528:DC%2BD1cXhtFKisLfI
9. Mu L, Katsaros D, Wiley A, Lu L, de la Longrais I, Smith S et al (2008) Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics. Breast Cancer Res Treat [Internet] (cited 2008 Sep 27). http://www.ncbi.nlm.nih.gov/pubmed/ 18481170
10. R Gentleman V Carey D Bates B Bolstad M Dettling S Dudoit, et al. 2004 Bioconductor: open software development for computational biology and bioinformatics Genome Biol 5 10 R80 15461798 10.1186/gb-2004-5-10-r80
11. P Du WA Kibbe SM Lin 2008 lumi: a pipeline for processing Illumina microarray Bioinformatics 24 13 1547 1548 18467348 10.1093/bioinformatics/btn224 1:CAS:528:DC%2BD1cXnvV2rtLg%3D (Pubitemid 351911712)
12. SM Lin P Du W Huber WA Kibbe 2008 Model-based variance-stabilizing transformation for Illumina microarray data Nucleic Acids Res 36 2 e11 18178591 10.1093/nar/gkm1075 (Pubitemid 351250461)
13. Smyth GK (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3(3)
14. Y Benjamini Y Hochberg 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing J R Stat Soc Ser B (Methodol) 57 1 289 300
15. The R Project for Statistical Computing. http://www.r-project.org )
16. Y Wang JGM Klijn Y Zhang AM Sieuwerts MP Look F Yang, et al. 2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 9460 671 679 15721472 1:CAS:528: DC%2BD2MXhsVOitLk%3D (Pubitemid 40260888)
17. MJ van de Vijver YD He LJ Van't Veer H Dai AAM Hart DW Voskuil, et al. 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 25 1999 2009 12490681 10.1056/NEJMoa021967 (Pubitemid 35461656)
18. K Chin S DeVries J Fridlyand PT Spellman R Roydasgupta W Kuo, et al. 2006 Genomic and transcriptional aberrations linked to breast cancer pathophysiologies Cancer Cell 10 6 529 541 17157792 10.1016/j.ccr.2006.10.009 1:CAS:528:DC%2BD28XhtlCnsrbF (Pubitemid 44854748)
19. JS Parker M Mullins MCU Cheang S Leung D Voduc T Vickery, et al. 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 8 1160 1167 19204204 10.1200/JCO.2008.18.1370
20. Ingenuity Pathways Analysis (IPA; Ingenuity Systems, Redwood City, CA). http://www.ingenuity.com
21. JL Resnik DB Reichart K Huey NJ Webster BL Seely 1998 Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer Cancer Res 58 6 1159 1164 9515800 1:CAS:528: DyaK1cXhvV2rsrs%3D (Pubitemid 28183203)
22. H Kim BC Litzenburger X Cui DA Delgado BC Grabiner X Lin, et al. 2007 Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-{kappa}B and snail Mol Cell Biol 27 8 3165 3175 17296734 10.1128/MCB.01315-06 1:CAS:528:DC%2BD2sXkt1OgtbY%3D (Pubitemid 46581327)
23. SE Dunn M Ehrlich NJ Sharp K Reiss G Solomon R Hawkins, et al. 1998 A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer Cancer Res 58 15 3353 3361 9699666 1:CAS:528:DyaK1cXltFyisr0%3D (Pubitemid 28371076)
24. X Zhang S Kamaraju F Hakuno T Kabuta S Takahashi D Sachdev, et al. 2004 Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression Breast Cancer Res Treat 83 2 161 170 14997047 10.1023/B:BREA.0000010709.31256.c6 1:CAS:528: DC%2BD2cXnvVKh (Pubitemid 38161263)
25. A Shin Z Ren X Shu Q Cai Y Gao W Zheng 2007 Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival Breast Cancer Res Treat 105 1 55 61 17066319 10.1007/s10549-006-9427-1 1:CAS:528:DC%2BD2sXptFehtbk%3D
26. S Kato Y Masuhiro M Watanabe Y Kobayashi KI Takeyama H Endoh, et al. 2000 Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways Genes Cells. 5 8 593 601 10947845 10.1046/j.1365-2443.2000. 00354.x 1:CAS:528:DC%2BD3cXmtleisb0%3D (Pubitemid 30641952)
27. H Huynh T Nickerson M Pollak X Yang 1996 Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780 Clin Cancer Res 2 12 2037 2042 9816164 1:CAS:528:DyaK2sXitlKqtw%3D%3D (Pubitemid 27006637)
28. AV Lee CN Weng JG Jackson D Yee 1997 Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells J Endocrinol 152 1 39 47 9014838 10.1677/joe.0.1520039 1:CAS:528: DyaK2sXivVKku7s%3D (Pubitemid 27026386)
29. AV Lee JG Jackson JL Gooch SG Hilsenbeck E Coronado-Heinsohn CK Osborne, et al. 1999 Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo Mol Endocrinol 13 5 787 796 10319328 10.1210/me.13.5.787 1:CAS:528:DyaK1MXivVyktL0%3D (Pubitemid 30645331)
30. A Decensi C Robertson B Ballardini D Paggi A Guerrieri-Gonzaga B Bonanni, et al. 1999 Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women Eur J Cancer 35 4 596 600 10492633 10.1016/S0959-8049(98)00428-6 1:CAS:528:DyaK1MXjtVGmsLY%3D (Pubitemid 29192968)
31. LC Happerfield DW Miles DM Barnes LL Thomsen P Smith A Hanby 1997 The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue J Pathol 183 4 412 417 9496257 10.1002/(SICI)1096- 9896(199712)183:4<412::AID-PATH944>3.0.CO;2-4 1:STN:280: DyaK1c7lslensA%3D%3D (Pubitemid 27509247)
32. J Ye S Liang N Guo S Li AM Wu S Giannini, et al. 2003 Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo Horm Metab Res 35 11-12 836 842 14710366 1:CAS:528:DC%2BD2cXpvVymtQ%3D%3D (Pubitemid 38058191)
33. S Ciarmatori D Kiepe A Haarmann U Huegel B Tönshoff 2007 Signaling mechanisms leading to regulation of proliferation and differentiation of the mesenchymal chondrogenic cell line RCJ3.1C5.18 in response to IGF-I J Mol Endocrinol 38 4 493 508 17446238 10.1677/jme.1.02179 1:CAS:528: DC%2BD2sXlsVWnsr8%3D (Pubitemid 46723264)
34. DZ Ewton S Kansra S Lim E Friedman 2002 Insulin-like growth factor-I has a biphasic effect on colon carcinoma cells through transient inactivation of forkhead1, initially mitogenic, then mediating growth arrest and differentiation Int J Cancer 98 5 665 673 11920634 10.1002/ijc.10229 1:CAS:528: DC%2BD38Xis1Wruro%3D (Pubitemid 34225616)
35. SM Rosenthal ZQ Cheng 1995 Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts Proc Natl Acad Sci USA 92 22 10307 10311 7479773 10.1073/pnas.92.22.10307 1:CAS:528:DyaK2MXovFaltr0%3D
36. Y Wei Y Chen D Li R Gu W Wang 2004 Dual effect of insulin-like growth factor on the apical 70-pS K channel in the thick ascending limb of rat kidney Am J Physiol Cell Physiol 286 6 C1258 C1263 15151916 10.1152/ajpcell.00441.2003 1:CAS:528:DC%2BD2cXkvFCqurY%3D (Pubitemid 38649975)
37. R Lupu M Cardillo C Cho L Harris M Hijazi C Perez, et al. 1996 The significance of heregulin in breast cancer tumor progression and drug resistance Breast Cancer Res Treat 38 1 57 66 8825123 10.1007/BF01803784 1:STN:280:DyaK28vit1GjtA%3D%3D (Pubitemid 26031066)
38. BM Marte M Jeschke D Graus-Porta D Taverna P Hofer B Groner, et al. 1995 Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells Mol Endocrinol 9 1 14 23 7760847 10.1210/me.9.1.14 1:CAS:528:DyaK2MXjsFGiu7c%3D
39. T Nagashima H Shimodaira K Ide T Nakakuki Y Tani K Takahashi, et al. 2007 Quantitative transcriptional control of ErbB receptor signaling undergoes graded to biphasic response for cell differentiation J Biol Chem 282 6 4045 4056 17142811 10.1074/jbc.M608653200 1:CAS:528:DC%2BD2sXht1Ojs7c%3D (Pubitemid 47084498)
40. A Staebler C Sommers SC Mueller S Byers EW Thompson R Lupu 1994 Modulation of breast cancer progression and differentiation by the gp30/heregulin [correction of neregulin] Breast Cancer Res Treat 31 2-3 175 182 7881097 10.1007/BF00666151 1:CAS:528:DyaK2MXit1altbk%3D (Pubitemid 24323459)
41. F Xu Y Yu XF Le C Boyer GB Mills RC Bast 1999 The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression Clin Cancer Res 5 11 3653 3660 10589783 1:CAS:528:DyaK1MXotV2gt78%3D
42. TC Hallstrom S Mori JR Nevins 2008 An E2F1-dependent gene expression program that determines the balance between proliferation and cell death Cancer Cell 13 1 11 22 18167336 10.1016/j.ccr.2007.11.031 1:CAS:528: DC%2BD1cXnsVKnug%3D%3D (Pubitemid 350309738)
43. E Mueller P Sarraf P Tontonoz RM Evans KJ Martin M Zhang, et al. 1998 Terminal differentiation of human breast cancer through PPAR[gamma] Mol Cell 1 3 465 470 9660931 10.1016/S1097-2765(00)80047-7 1:CAS:528:DyaK1cXhtlyhurk%3D (Pubitemid 128378895)
44. J Massagué 2008 TGF[beta] in cancer Cell 134 2 215 230 18662538 10.1016/j.cell.2008.07.001 (Pubitemid 352010335)
45. M Oft J Peli C Rudaz H Schwarz H Beug E Reichmann 1996 TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells Genes Dev 10 19 2462 2477 8843198 10.1101/gad.10.19.2462 1:CAS:528:DyaK28Xmt1KnurY%3D (Pubitemid 26341881)
46. D Danielpour K Song 2006 Cross-talk between IGF-I and TGF-[beta] signaling pathways Cytokine Growth Factor Rev 17 1-2 59 74 16297654 10.1016/j.cytogfr.2005.09.007 1:CAS:528:DC%2BD28Xos1Crtw%3D%3D (Pubitemid 43117516)
47. Jassem J, Langer CL, Karp DD, Mok T, Novello S, Park K, Strausz J, Benner RJ, Green S, Gualberto A (2010) Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). American Society of Clinical Oncology Annual Meeting 2010. Abstract #7500, Chicago